Skip to content

Clinical research on non-alcoholic fatty liver disease related diseases

Development of early screening and diagnostic kit for cardiovascular diseases associated with non-alcoholic fatty liver disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039688
Enrollment
Unknown
Registered
2020-11-05
Start date
2020-10-30
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

Normal group:Nil
Simple fatty liver group:Nil
fatty liver combined with carotid artery disease group:Nil

Sponsors

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Normal group selection criteria 1. Age > 18 years old, 18 years old, 18 years old, 1.0mm or carotid artery plaque; 4. Patients with better compliance; 5. Have read and signed the informed consent; If the answer to any of the above questions is "No", the case cannot be included in the study. Inclusion criteria for coronary heart disease group 1. Age > 18 years old, = 0.1mV, or T wave inversion >= 0.2mV); cTnT, cTnI, CK-MB increase; coronary angiogram revealed related lesions. (3) Acute ST-segment elevation myocardial infarction: typical clinical manifestations, electrocardiogram changes, laboratory examinations. 3. B-ultrasound results/fibrotouch prompts fatty liver; 4. Patients with better compliance; 5. Have read and signed the informed consent; If the answer to any of the above questions is "No", the case cannot be included in the study.

Exclusion criteria

Exclusion criteria: 1. Patients with other heart diseases (such as heart failure, valvular disease, cardiomyopathy, etc.); 2. Patients with other liver diseases (such as liver cancer, cirrhosis, hepatitis B, etc.); 3. Patients with other serious organic diseases such as lung, kidney, brain. If the answer to any of the above questions is "yes", the case cannot be included in the study.

Design outcomes

Primary

MeasureTime frame
CCA-IMT;ICA-IMT;Liver stiffness;Liver fat attenuation value;

Countries

China

Contacts

Public ContactLing Yang

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

hepayang@163.com+86 13971178791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026